The global breast biopsy market size was US$ 692.3 million in 2021. The global breast biopsy market size is forecast to reach US$ 1092.44 million by 2030, growing at a compound annual growth rate (CAGR) of 5.2% during the forecast period from 2022 to 2030.

Breast biopsies typically detect cancer in the breast, but they can also use to detect other diseases discovered during a physical examination. A breast biopsy is a diagnostic procedure used to determine whether a small sample of breast tissue is malignant or not. Breast biopsies are one of the most effective ways of detecting cancer. Approximately 70-80% of biopsy results are cancer-free, although they may reveal predispositions to mammary carcinoma. An individual experiencing symptom such as a breast lump, sore breast, dimpling of the breast, peeling of the breast, and nipple discharge requires a breast biopsy.

Factors Influencing Market Growth 

• Among the factors driving the market's growth are the rising incidence of breast cancer, the growing demand for minimally invasive and non-invasive procedures, and the rising number of breast cancer screenings. According to the WHO data, there were 2.3 million breast cancer diagnoses in 2020 and 685 000 deaths due to breast cancer. By the end of 2020, 7.8 million women alive have been diagnosed with breast cancer in the previous five years, making it the most prevalent cancer in the world.
• The risk of adverse effects and infections after biopsies may slow down the overall market growth.
• Technology advancements and an increase in adaptive mammography-guided stereotactic biopsy are forecast to lead to significant market growth in the near future.

Impact Analysis of COVID-19

COVID-19 pandemic has negatively impacted breast biopsy market growth in a number of ways. As a result of lockdowns in several nations to prevent the spread of COVID-19, hospitals, clinics, and diagnostic centers were unable to provide biopsy services. In addition, the delay in treatments and the priority given to COVID diagnosis led to a negative impact on the market. Although there was a relaxation of the pandemic situation, the hospitals concentrated on the delayed appointments, which helped the market regain its growth. 

Regional Insights

North America dominated the global breast biopsy market in terms of revenue in 2021, and this dominance is forecast to continue over the forecast period. As a result of the early adoption of newer breast biopsy technologies, continued technological advances, rising breast cancer incidence, and the rapidly aging population more prone to contracting breast cancer, the region has a large share of the demand for breast biopsy services.

Leading Competitors

The leading prominent companies profiled in the global breast biopsy market are:

• Ethicon Endo Surgery
• Intact Medical Corporation
• Galini SRL
• Hologic Incorporated
• Leica Biosystems Nussloch GmbH
• C. R. Bard, Incorporated
• Becton and Dickinson Company
• Argon Medical Devices
• Cook Medical Incorporated
• Encapsule Medical Devices, LLC
• Other Prominent Players

Scope of the Report

The global breast biopsy market segmentation focuses on Product, Image Guided Technology, End-User, and Region.

Segmentation based on Product

• Vacuum Assisted Biopsy
• Core Needle Biopsy
• Fine Needle Aspiration Biopsy

Segmentation based on Image Guided Technology

• MRI Guided Breast Biopsy
• Ultrasound Guided Breast Biopsy
• Mammography Guided Stereotactic Biopsy
• Ct Guided Biopsy
• Other Image Guided Breast Biopsy

Segmentation based on End-User

• Hospitals And Clinics
• Diagnostic Centers

Segmentation based on Region

• North America
• The U.S.
• Canada
• Mexico
• Europe
• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe
• Asia Pacific
• China
• India
• Japan
• Australia & New Zealand
• ASEAN
• Rest of Asia Pacific
• Middle East & Africa (MEA)
• UAE
• Saudi Arabia
• South Africa
• Rest of MEA
• South America
• Brazil
• Argentina
• Rest of South America